Association between ADAMTS-13 Activity and the Prognosis of Multiple Myeloma after Bone Marrow Transplantation | ||||
| Ain Shams Medical Journal | ||||
| Volume 74, Issue 4, December 2023, Page 1053-1062 PDF (381.82 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/asmj.2023.238863.1173 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Nahed Moawad Ibrahim Ibrahim Rakha 1; Essam Abdel Wahid Hassan1; Nermeen Adel Nabeeh Abdelghaffar1; Ahmed Sabry Ali Mubarak  2; Gehad Hamada Fekry Hafez1
| ||||
| 1Department of Internal Medicine and Clinical Haematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. | ||||
| 2Clinical Haematology department, Nasser Institute, Cairo, Egypt. | ||||
| Abstract | ||||
| Introduction: Multiple myeloma is one of the commonest hematological neoplasms. Auto stem cell transplantation is currently the standard plan of care as consolidation in fit eligible patients after receiving induction chemotherapy. Aim of the work: This aim of this study is assessment the significance and validity of pre auto hematopoietic stem cell transplantation plasma level of ADAMTS-13 activity to predict the prognosis (outcome, disease free survival) and complications (including transplant related mortality, relapse) of multiple myeloma patients. Patients and Methods: In this prospective Cohort study, pre transplantation plasma level of ADMATS13 was studied for its potential effect on the survival, incidence of MM relapse and outcome of auto hematopoietic stem cell transplantation. The study took place in a single bone marrow transplantation facility and included 51 patients previously diagnosed with MM, received induction chemotherapy, and admitted for ASCT. Results: Blood samples were collected prior to transplantation and the patients were followed up throughout the transplantation process and till 12 months after transplantation. ADAMTS-13 levels came between 24.6% and 152.4%. The average level was 74.78%, with half of patients below 64.77%. 12 out of 51 patients (23.5%) had ADAMTS-13 level below 50%. 44 out of 51 patients (86.3%) survived though the follow up period without any evidence of relapse. Only 7 patients (13.7%) had MM relapse. Conclusion: The pre transplantation plasma level of ADAMTS-13 has no statistically significant effect on the outcome, relapse incidence or disease-free survival during the first 12 months after transplantation. | ||||
| Keywords | ||||
| ADAMTS-13; Multiple Myeloma; Bone Marrow Transplantation | ||||
|
Statistics Article View: 194 PDF Download: 162 |
||||
